1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Spine Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Spine Biologics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. Technological Advancements
5.2. Reimbursement Scenario by Region/Globally
5.3. Regulatory Scenario by Region/Globally
5.4. Pipeline Analysis
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Spine Biologics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Bone Allografts
6.3.2. Bone Graft Substitute
6.3.3. Platelet Rich Plasma
6.3.4. Bone Marrow Aspirate Therapy
6.3.5. Demineralized Bone Matrix (DBM)
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Spine Biologics Market Analysis and Forecast, by Surgery Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Surgery Type, 2017-2031
7.3.1. Minimally Invasive Surgery
7.3.2. Open Surgery
7.4. Market Attractiveness Analysis, by Surgery Type
8. Global Spine Biologics Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Spinal Fusion
8.3.2. Spinal Non-union & Fracture Repair
8.3.3. Degenerative Disc Disease Treatment
8.3.4. Other Applications
8.4. Market Attractiveness Analysis, by Application
9. Global Spine Biologics Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Spinal Surgery Centers
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Spine Biologics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Spine Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Bone Allografts
11.2.2. Bone Graft Substitute
11.2.3. Platelet Rich Plasma
11.2.4. Bone Marrow Aspirate Therapy
11.2.5. Demineralized Bone Matrix (DBM)
11.2.6. Others
11.3. Market Value Forecast, by Surgery Type, 2017-2031
11.3.1. Minimally Invasive Surgery
11.3.2. Open Surgery
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Spinal Fusion
11.4.2. Spinal Non-union & Fracture Repair
11.4.3. Degenerative Disc Disease Treatment
11.4.4. Other Applications
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Spinal Surgery Centers
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Surgery Type
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Spine Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Bone Allografts
12.2.2. Bone Graft Substitute
12.2.3. Platelet Rich Plasma
12.2.4. Bone Marrow Aspirate Therapy
12.2.5. Demineralized Bone Matrix (DBM)
12.2.6. Others
12.3. Market Value Forecast, by Surgery Type, 2017-2031
12.3.1. Minimally Invasive Surgery
12.3.2. Open Surgery
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Spinal Fusion
12.4.2. Spinal Non-union & Fracture Repair
12.4.3. Degenerative Disc Disease Treatment
12.4.4. Other Applications
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Spinal Surgery Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Surgery Type
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Spine Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Bone Allografts
13.2.2. Bone Graft Substitute
13.2.3. Platelet Rich Plasma
13.2.4. Bone Marrow Aspirate Therapy
13.2.5. Demineralized Bone Matrix (DBM)
13.2.6. Others
13.3. Market Value Forecast, by Surgery Type, 2017-2031
13.3.1. Minimally Invasive Surgery
13.3.2. Open Surgery
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Spinal Fusion
13.4.2. Spinal Non-union & Fracture Repair
13.4.3. Degenerative Disc Disease Treatment
13.4.4. Other Applications
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Spinal Surgery Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Surgery Type
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Spine Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Bone Allografts
14.2.2. Bone Graft Substitute
14.2.3. Platelet Rich Plasma
14.2.4. Bone Marrow Aspirate Therapy
14.2.5. Demineralized Bone Matrix (DBM)
14.2.6. Others
14.3. Market Value Forecast, by Surgery Type, 2017-2031
14.3.1. Minimally Invasive Surgery
14.3.2. Open Surgery
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Spinal Fusion
14.4.2. Spinal Non-union & Fracture Repair
14.4.3. Degenerative Disc Disease Treatment
14.4.4. Other Applications
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Spinal Surgery Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Surgery Type
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Spine Biologics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Bone Allografts
15.2.2. Bone Graft Substitute
15.2.3. Platelet Rich Plasma
15.2.4. Bone Marrow Aspirate Therapy
15.2.5. Demineralized Bone Matrix (DBM)
15.2.6. Others
15.3. Market Value Forecast, by Surgery Type, 2017-2031
15.3.1. Minimally Invasive Surgery
15.3.2. Open Surgery
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Spinal Fusion
15.4.2. Spinal Non-union & Fracture Repair
15.4.3. Degenerative Disc Disease Treatment
15.4.4. Other Applications
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Spinal Surgery Centers
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Surgery Type
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Johnson And Johnson (Depuy Synthes)
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Orthofix Medical Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Stryker Corporation
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Zimmer Biomet
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Arthrex, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Exactech, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Spine Wave, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Medtronic plc
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. NuVasive, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
